| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 15,088 | 19,703 | ||
| Investment securities | 190,882 | 196,573 | ||
| Prepaid expenses and other current assets | 3,059 | 3,518 | ||
| Total current assets | 209,029 | 219,794 | ||
| Property and equipment | 3,212 | - | ||
| Less accumulated depreciation | 2,108 | - | ||
| Property and equipment, net | 1,104 | 1,258 | ||
| Right-of-use asset, related party | 1,637 | 1,834 | ||
| Other assets | 0 | 0 | ||
| Total assets | 211,770 | 222,886 | ||
| Accounts payable | 1,913 | 1,013 | ||
| Accrued expenses and other current liabilities (including related party amounts of 866 and 800 respectively) | 9,260 | 7,734 | ||
| Total current liabilities | 11,173 | 8,747 | ||
| Operating lease liability, net, related party | 877 | 1,102 | ||
| Total liabilities | 12,050 | 9,849 | ||
| Common stock, 0.0001 par value 200,000,000 shares authorized at september 30, 2025 and december 31, 2024 56,963,757 and 56,754,341 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 6 | 6 | ||
| Additional paid-in capital | 480,365 | 476,738 | ||
| Accumulated deficit | -281,009 | -264,012 | ||
| Accumulated other comprehensive income | 358 | 305 | ||
| Total stockholders' equity | 199,720 | 213,037 | ||
| Total liabilities and stockholders' equity | 211,770 | 222,886 | ||
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)